Anti-cancer effects of F16: A novel vascular endothelial growth factor receptor–specific inhibitor

Anti-cancer effects of F16: A novel vascular endothelial growth factor receptor–specific inhibitor

Vascular endothelial growth factor receptor-2 is a dynamic target for therapeutic intervention in various types of cancers. This study was aimed to explore the anti-angiogenic activity of a novel vascular endothelial growth factor receptor–specific inhibitor named F16 in both in vitro and in vivo ex...

Full description

Saved in:

Bibliographic Details
Main Authors:	Appu Rathinavelu, Khalid Alhazzani, Sivanesan Dhandayuthapani, Thanigaivelan Kanagasabai
Format:	Article
Language:	English
Published:	SAGE Publishing 2017-11-01
Series:	Tumor Biology
Online Access:	https://doi.org/10.1177/1010428317726841
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Differential Effector Function of Tissue-Specific Natural Killer Cells against Lung Tumors
by: Zerick Terrell Dunbar, et al.
Published: (2024-01-01)

Vascular Endothelial Growth Factor Receptors in the Vascularization of Pancreatic Tumors: Implications for Prognosis and Therapy
by: Craig Grobbelaar, et al.
Published: (2025-03-01)

Artificial intelligence system for predicting hand-foot skin reaction induced by vascular endothelial growth factor receptor inhibitors
by: Taro Yamanaka, et al.
Published: (2025-03-01)

Vascular endothelial growth factor inhibitors in the treatment of ovarian cancer
by: S. V. Khokhlova
Published: (2014-08-01)

Vascular Endothelial Growth Factor Receptor-1 Expression in Breast Cancer and Its Correlation to Vascular Endothelial Growth Factor A
by: Nahida Srabovic, et al.
Published: (2013-01-01)

Anti Vascular Endothelial Growth Factor Agents in Corneal Neovascularization
by: Srivatsa Sehra, et al.
Published: (2011-07-01)

A pharmacovigilance study of thromboembolism events associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors based on FAERS database
by: Zongwei Tang, et al.
Published: (2025-07-01)

Effect of the Vascular Endothelial Growth Factor Inhibitor Toceranib on Cardiac Function and Endothelial Dysfunction Biomarkers in Dogs With Cancer
by: Katherine E. Lopez, et al.
Published: (2025-05-01)

Early detection of pulmonary arterial hypertension through [18F] positron emission tomography imaging with a vascular endothelial receptor small molecule
by: Zhen Yang, et al.
Published: (2024-07-01)

The Use of Vascular Endothelial Growth Factor Inhibitors in Patients with Proliferative Diabetic Retinopathy
by: V. Yu. Evgrafov, et al.
Published: (2022-07-01)

Identification of nitric oxide as an endogenous inhibitor of 26S proteasomes in vascular endothelial cells.
by: Hongtao Liu, et al.
Published: (2014-01-01)

Vascular Endothelial Growth Factor (VEGF) Family and the Immune System: Activators or Inhibitors?
by: Cristina Maria Failla, et al.
Published: (2024-12-01)

Risks of proteinuria associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: a systematic review and meta-analysis.
by: Ze-Feng Zhang, et al.
Published: (2014-01-01)

Vascular Endothelial Growth Factor Inhibitor-Induced Hypertension: Basics for Primary Care Providers
by: Carmen P. Escalante, et al.
Published: (2011-01-01)

Liver function dynamics in advanced hepatocellular carcinoma receiving immune checkpoint inhibitors and anti-vascular endothelial growth factor antibody/tyrosine kinase inhibitors with or without transarterial chemoembolization
by: Chen-You Liu, et al.
Published: (2025-06-01)

Vascular cell‐specific roles of mineralocorticoid receptors in pulmonary hypertension
by: Divya P. Menon, et al.
Published: (2021-07-01)

CLINICAL ASSOCIATIONS OF VASCULAR ENDOTHELIAL GROWTH FACTOR AND ITS TYPE 2 RECEPTOR IN SYSTEMIC SCLEROSIS
by: R. T. Alekperov, et al.
Published: (2018-11-01)

Vascular endothelial growth factor receptor-2 couples cyclo-oxygenase-2 with pro-angiogenic actions of leptin on human endothelial cells.
by: Elena Garonna, et al.
Published: (2011-04-01)

Photodynamic therapy combined with anti-vascular endothelial growth factor therapy for pachychoroid neovasculopathy.
by: Akiko Miki, et al.
Published: (2021-01-01)

Risk of artery dissection during systemic exposure to vascular endothelial growth factor pathway inhibitors
by: Jun Okui, et al.
Published: (2024-12-01)

Bee pollen peptides as potent tyrosinase inhibitors with anti-melanogenesis effects in murine b16f10 melanoma cells and zebrafish embryos
by: Papassara Sangtanoo, et al.
Published: (2024-12-01)

Sitagliptin Accelerates Endothelial Regeneration after Vascular Injury Independent from GLP1 Receptor Signaling
by: Friederike Remm, et al.
Published: (2018-01-01)

Evaluation of epigenetic inactivation of vascular endothelial growth factor receptors in head and neck squamous cell carcinoma
by: Yuki Misawa, et al.
Published: (2017-07-01)

Targeting Vascular Endothelial Growth Factor Receptor 2 (VEGFR-2): Latest Insights on Synthetic Strategies
by: Carolina S. Marques, et al.
Published: (2024-11-01)

Refractive errors in premature infants with retinopathy of prematurity after anti-vascular endothelial growth factor (anti-VEGF) therapy
by: Vujanović Milena S., et al.
Published: (2017-01-01)

Idiopathic Choroidal Neovascular Membrane In Young Treated With Minimum Anti Vascular Endothelial Growth Factor
by: Rahul Kumar Sharma, et al.
Published: (2017-10-01)

Angiogenesis impairment in diabetes: role of methylglyoxal-induced receptor for advanced glycation endproducts, autophagy and vascular endothelial growth factor receptor 2.
by: Hongtao Liu, et al.
Published: (2012-01-01)

Systematic review of the risk of adverse outcomes associated with vascular endothelial growth factor inhibitors for the treatment of cancer.
by: Labib Imran Faruque, et al.
Published: (2014-01-01)

Anti-Melanogenic Effects of L-Theanine on B16F10 Cells and Zebrafish
by: Chih-Li Yu, et al.
Published: (2025-02-01)

Predictive Significance of Vascular Endothelial Growth Factor receptor VEGF-2 in triple-negative breast cancer patients
by: N. N. Babyshkina, et al.
Published: (2016-11-01)

Soluble vascular endothelial growth factor receptor 1 (VEGFR1): A possible biomarker in BPS/IC?
by: Pedro Abreu-Mendes, et al.
Published: (2025-06-01)

Placental expression of estrogen and progesterone receptors and vascular endothelial growth factor in buffaloes suffering from uterine torsion
by: Yahia A. Amin, et al.
Published: (2025-02-01)

Microultrasound Molecular Imaging of Vascular Endothelial Growth Factor Receptor 2 in a Mouse Model of Tumor Angiogenesis
by: Joshua J. Rychak, et al.
Published: (2007-09-01)

Incidence of Endophthalmitis after Intravitreal Anti-Vascular Endothelial Growth Factor Injections in an Operating Room in China
by: Yanyun Chen, et al.
Published: (2020-01-01)

The Economic Burden of Anti-Vascular Endothelial Growth Factor on Patients and Caregivers in the UK, Europe, and North America
by: David Tabano, et al.
Published: (2025-06-01)

Serologic parameters in young patients with retinal vein occlusion treated with anti-vascular endothelial growth factor
by: Tong-Tong Niu, et al.
Published: (2025-03-01)

Intravitreal anti-vascular endothelial growth factor therapy in the treatment of vision loss associated with hematologic malignancy
by: Thomas P. Toohey, et al.
Published: (2024-12-01)

IMA Genome - F16
by: Brenda D. Wingfield, et al.
Published: (2022-02-01)

Correction: Placental expression of estrogen and progesterone receptors and vascular endothelial growth factor in buffaloes suffering from uterine torsion
by: Yahia A. Amin, et al.
Published: (2025-04-01)

Targeting Tumor Endothelial Cells by EGCG Using Specific Liposome Delivery System Inhibits Vascular Inflammation and Thrombosis
by: Zi Jia, et al.
Published: (2024-12-01)